Expertise in
2
conditions

Marit Ahrens

Arnold Heller Str. 3, 
Kiel, SH, DE 
Expertise in
2
conditions
Arnold Heller Str. 3, 
Kiel, SH, DE 

Overview

Marit Ahrens practices practicing medicine in Kiel, Germany.

Ms. Ahrens is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Adult Soft Tissue Sarcoma, Angiosarcoma, Prostate Cancer, and Prostatectomy.

She is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Arnold Heller Str. 3, Kiel, SH 24105, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial
Enrollment Status: Terminated
Publish Date: September 22, 2021
Intervention Type: Drug
Study Drug: Pazopanib
Study Phase: Phase 4
View 1 Less Clinical Trial

27 Total Publications

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.
Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.
Journal: Cancer treatment and research communications
Published: May 03, 2026

Frequently Asked Questions about Marit Ahrens

Is Marit Ahrens a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Marit Ahrens is classified as an Advanced expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marit Ahrens participate in research or clinical trials?

Yes. Marit Ahrens has published 27 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Marit Ahrens's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ahrens's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile